Suite 119, 3553 31 Street NW
8 articles about Parvus Therapeutics
Hugh Young Rienhoff, Jr., M.D., appointed as Chairman of the Board Charles A. Johnson, M.D., appointed to Board of Directors Alain Delcayre, Ph.D., appointed Senior Vice President of Research
Parvus Therapeutics Publication of Preclinical Proof-of-Concept Research that Underlies the Development of Navacim™ Therapeutics for the Treatment of Autoimmune Liver Diseases
Research underpins part of the recently executed license and collaboration agreement to develop, manufacture and commercialize Navacim™ therapeutics for treatment of gastrointestinal inflammatory diseases, including autoimmune liver disease
Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim™ Therapeutics for the Treatment of Autoimmune Diseases
Parvus Eligible to Receive Upfront and Milestone Payments Exceeding $800 Million Plus Royalties on Net Sales
Financial terms of the deal were not disclosed, but Genentech aims to use Parvus' technology to target IBD and Celiac.
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
Parvus is advancing a therapeutic pipeline of novel class of disease-modifying therapeutics – Navacims™ – toward clinical testing for the treatment of diverse autoimmune diseases
Parvus Therapeutics Announces Exclusive Worldwide License And Collaboration Agreement For The Development And Commercialization Of Its Lead Nanomedicine To Treat Type 1 Diabetes
Parvus Therapeutics ' Nanotechnology Treatment Reprograms Immune Cells To Reverse Autoimmune Disease, As Published In Nature